On August 29, 2025 ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, reported that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York (Press release, ALX Oncology, AUG 29, 2025, View Source [SID1234655580]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the meetings are as follows:

Cantor Global Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, September 3, 2025
Location: New York, NY
Time of Fireside Chat Presentation: 9:45 AM ET
Webcast link: Available here

H.C. Wainwright 27th Annual Global Investment Conference

Format: One-on-one meetings
Date: Tuesday, September 9, 2025
Location: New York, NY
Webcast link: Pre-recorded fireside chat presentation available here

The webcasts of the Cantor and H.C. Wainwright fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the fireside chat dates.

On August 29, 2025 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that members of its management team will participate in upcoming investor conferences in September 2025 (Press release, Abeona Therapeutics, AUG 29, 2025, View Source [SID1234655579]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2025: Fireside chat on Thursday, September 4, 2025 at 10:20 a.m. ET and investor meetings.
H.C. Wainwright 27th Annual Global Investment Conference: Company presentation on Tuesday, September 9, 2025 at 2:00 p.m. ET and investor meetings.

A live webcast of the presentation and fireside chat can be accessed on the Investors section of the Abeona website under "Events" at View Source, where a replay of the events will also be available for a limited time.

On August 28, 2025 PureTech Health reported half yearly report.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, PureTech Health, AUG 28, 2025, View Source [SID1234661833])

On August 28, 2025 Stada, a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals, reported the company achieved strong revenues and earnings growth in the financial first half ended 30 June 2025 (Press release, Stada, AUG 28, 2025, View Source [SID1234656740]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 28, 2025 Tidewave Bio, a biotechnology company developing a universal, off-the-shelf, gene-enhanced antigen-presenting cell therapy platform, reported the successful completion of its FDA INTERACT meeting (Press release, Tidewave Bio, AUG 28, 2025, https://www.globenewswire.com/news-release/2025/08/28/3140757/0/en/Tidewave-Bio-Completes-FDA-INTERACT-Meeting-for-TBC-1-a-Universal-Cell-Therapy-Platform-in-Solid-Tumors.html?utm_source=chatgpt.com [SID1234656369]). This milestone provides critical regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tidewave Bio’s platform is designed to address one of the greatest challenges in oncology: effective and accessible treatment for solid tumors. Unlike current therapies that target limited antigens or require patient-specific manufacturing, Tidewave’s universal cell therapy is tumor type–agnostic, cost-reducing, and available in real time. By delivering a broad repertoire of tumor antigens, the platform is designed to activate robust and durable immune responses across a wide range of cancers.

"We are proactively engaging with the FDA as an external validation of our risk-mitigation strategy during product development," said Francois Binette, PhD, Chief Executive Officer and Co-Founder. "The feedback from our INTERACT meeting provides clarity and confidence as we progress toward IND-enabling activities. Our mission is to expand access to advanced therapies for all solid tumor patients, and today we are one step closer to that goal."

Tidewave Bio will integrate FDA feedback into its development program and pursue a pre-IND meeting to further shape its regulatory strategy. The company intends to work closely with regulatory agencies in the U.S. and abroad throughout product development to progressively de-risk its innovative program toward successful IND/CTA submissions.